Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

@article{Zhao2011ActivityOP,
  title={Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.},
  author={Chen Xing Zhao and Suhn Hee Kim and Sung Won Lee and Ju-Hong Jeon and Kyung Ku Kang and Sung Beom Choi and Jong Kwan Park},
  journal={BJU international},
  year={2011},
  volume={107 12},
  pages={1943-7}
}
OBJECTIVE • To evaluate the impact and distribution of a single phosphodiesterase type 5 inhibitor (PDE5 I) dose (udenafil or tadalafil) in prostate tissue and plasma in patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS • Thirty BPH patients complaining of erectile dysfunction along with moderate-to-severe lower urinary tract symptoms (LUTS) who underwent transurethral resection of the prostate (TURP) were enrolled in the present study. • The patients were randomly… CONTINUE READING